Investigating how Trop-2 affects advanced prostate cancer treatment
Official title: Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches
Funded at University of Wisconsin-Madison · NIH-10873817 · Data updated 2026-11-12
This study is looking at why some advanced prostate cancer treatments don't work as well for certain patients, especially those with a tough form of the disease, and it hopes to find new ways to help improve their treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $625,914 |
| NIH project number | 5R01CA276269-02 |
| Project ID | NIH-10873817 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with metastatic castrate resistant prostate cancer who have limited treatment options.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have metastatic disease may not benefit from this research.
What this research studies
This research focuses on understanding the molecular mechanisms behind treatment resistance in advanced prostate cancer, particularly in patients with metastatic castrate resistant prostate cancer (mCRPC). By examining the role of Trop-2 and other molecular factors, the study aims to identify new therapeutic strategies that could improve patient outcomes. The approach includes analyzing genomic and epigenomic changes in cancer cells to uncover potential vulnerabilities that can be targeted with new treatments. Patients may be involved in clinical trials that test these innovative therapies.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve survival and quality of life for men with advanced prostate cancer.
How similar studies have gone: Previous research has shown promise in targeting molecular mechanisms in advanced prostate cancer, indicating potential for success with this approach.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Lang, Joshua Michael — University of Wisconsin-Madison
- Study coordinator: Lang, Joshua Michael
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.